Seegene, Inc. Announces Publication Of MuDT™ Technology In Nature’s Scientific Reports Journal

GAITHERSBURG, MD and SEOUL, SOUTH KOREA--(Marketwired - December 15, 2014) -

Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplex PCR technologies, today announced the publication of its innovative “MuDT™" technology in Scientific Reports, the open access journal from the publishers of Nature [Article number: 7439 doi:10.1038/srep07439].

Seegene’s Multiple Detection Temperatures (MuDT™) technology is an innovative next-generation qPCR technology that allows simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis after amplification. Using MuDT™ technology provides a powerful and cost-effective path to upgrading any real-time PCR instrument, doubling its multiplexing capacity without any changes the number of channels used.

MuDT™ technology will accelerate a paradigm shift in clinical diagnostics by delivering more comprehensive and actionable diagnostics, leading to improved patient care and reduced healthcare costs.

“Seegene expends tremendous effort to continually develop and commercialize innovative PCR chemistry technologies that improve clinical molecular diagnostics. We are very pleased by the resulting academic and commercial adoption of technologies and products,” said Dr. Chun, Jong-Yoon, Founder and CEO of Seegene.

Dr. Chun continued, “Our recently announced supply agreement with Beckman Coulter, new U.S. patent for Tagging Oligonucleotide Cleavage & Extension (TOCE™) technology, and this publication of MuDT™ technology are all meaningful milestones ahead of Seegene’s planned entry into the U.S. market and potential partnerships with leading In-Vitro Diagnostics players.”

In November of this year, Seegene also unveiled the first of three comprehensive Allplex™ assays, a 26-target Respiratory Panel. This panel will be followed by a 26-target Gastrointestinal Infection Panel and a 27-target Sexually Transmitted Infection Panel in early 2015. Seegene will continue to expand its Allplex family of infectious disease panel tests, and aims to receive CE Mark on the first three assays in 2015.

About Seegene
Seegene is the world’s leading developer of multiplex molecular technologies and multiplexed clinical molecular diagnostics. Seegene’s innovative proprietary technologies, including DPO™, TOCE™, mTOCE™ and MuDT™, can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene endlessly strives toward the new possibility of a world free of disease.

For more information, please visit www.seegene.com or call +301-762-9066.